Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations

Abstract

Lysosphingolipid accumulations in PD patients who bear glucocerebrosidase 1 mutations suggest that substrate reduction therapy might be viewed as a possible strategy for glucocerebrosidase 1-PD treatment. © 2018 International Parkinson and Movement Disorder Society.